JAK Janus Kinase

Aus coViki
Wechseln zu: Navigation, Suche
GET 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. Extract
  • GET ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 Extract
  • GET ä. Potential role of Janus kinase inhibitors in COVID-19 Extract
  • GET ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 Extract
GET 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. Extract
  • GET 2020. ...The potential role of JAK inhibitors in the management of COVID-19. Extract
  • GET 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Extract
  • GET 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia]. Extract
  • GET 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19. Extract
  • GET 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Extract


Tofacitinib

  • GET ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib Extract

Baricitinib

  • GET ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19 Extract
  • GET ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact Extract
  • GET 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Extract
  • GET 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. Extract
  • GET 2020. Baricitinib for COVID-19: a suitable treatment? Extract
  • GET 2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply Extract
  • GET 2020. Baricitinib: A chance to treat COVID-19? Extract
  • GET 2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19. Extract
  • GET 2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19. Extract
  • GET 2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia. Extract
  • GET 2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2. Extract

Fedratinib

GET ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Extract

Ruxolitinib

  • GET 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports. Extract
  • GET 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Extract
  • GET 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Extract
  • GET 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Extract
  • GET 2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation. Extract
  • GET 2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Extract
  • GET 2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Extract
  • GET 2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Extract
  • GET 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Extract

Jaktinib

  • GET 2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. Extract


Methotrexate mtx

  • GET 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge